Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Income from Continuing Operations (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Income from Continuing Operations readings, the most recent being 9319000.0 for Q4 2023.

  • On a quarterly basis, Income from Continuing Operations fell 55.37% to 9319000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 36434000.0, a 5.24% decrease, with the full-year FY2025 number at 38847000.0, up 14.51% from a year prior.
  • Income from Continuing Operations hit 9319000.0 in Q4 2023 for Elicio Therapeutics, up from 10526000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 14634000.0 in Q4 2021 to a low of 19939000.0 in Q1 2021.
  • Median Income from Continuing Operations over the past 4 years was 11055500.0 (2020), compared with a mean of 10352125.0.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 205.66% in 2021 and later crashed 140.99% in 2022.
  • Elicio Therapeutics' Income from Continuing Operations stood at 13850000.0 in 2020, then skyrocketed by 205.66% to 14634000.0 in 2021, then crashed by 140.99% to 5998000.0 in 2022, then tumbled by 55.37% to 9319000.0 in 2023.
  • The last three reported values for Income from Continuing Operations were 9319000.0 (Q4 2023), 10526000.0 (Q3 2023), and 8452000.0 (Q2 2023) per Business Quant data.